It gives a lot of data on chances of symptoms and illness at various periods after the first and second doses from various studies, however the bottom line is that long term the national level studies show that:
“The vaccine also provided 97.2% protection against hospitalisation overall and 97.5% protection against severe and critical hospitalisation.”
These are outstanding results, among the best of any vaccine ever developed, and from studies of large a large and diverse population.
It was 100% effective is a study of 2,000 12-15 year olds. This is important because in countries like Brazil where the death rate is incredibly high, even the small fraction of victims that are children adds up to many hundreds, or even thousands of deaths.